Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Biology Research

Biology Research

Our Biology Department boasts a variety of technical solutions, professional scientific research teams, various advanced instruments and biological laboratories. Medicilon has broad experience in fields such as molecular biology, cell biology, in vitro biology, and structural biology.

With our technical platforms such as enzyme level and cell level measurement platforms, we can enable our clients to select compounds and research their properties, action mechanism and provide bio-marker analysis, thus ensuring the effective implementation of our clients' projects and helping promote the process of drug R&D.

Biology Service Model & Advantages
  • biology.wenp
    biology.wenp
    Biology Division has been dedicated to drug discovery services for over 19 yearsServing over 300 clients annuallyOver 1000 screening methods established, generating over 2 million data points per yearConducted conformational studies for more than 200 targetsCell library with over 400 tumor cell lines for drug sensitivity testingRich knowledge base with more than 50 new experimental methods and 5 new platforms per yearClinical biomarker detection system has been gradually improved, with the ability to detect biomarkers in human blood and tissue samples, and NanoString nCounter tissue mRNA detection platform is under preparation
Feature Platform
  • Kinase Screening PlatformEnzymatic/Molecular Interaction Screening PlatformCell Screening PlatformSmall Nucleic Acid Platform
In Vitro Evaluation of PROTAC Molecules

PROTAC (proteolysis-targeting chimera) are bifunctional specific small molecules that can target otherwise undruggable target proteins for degradation, thereby reducing their biological activity in a cell. It can be understood as a dumbbell-shaped chimera, of which one end is used to target the target protein to be degraded, the other end is used to recruit protein degradation systems like E3 ubiquitin ligase and both ends are connected by a suitable linker. Therefore, a ternary chimera is formed featuring target protein - PROTAC - E3 ubiquitin ligase that ensures close connection between target protein and E3 ligase, so that the target protein can be ubiquitinated and then further recognized and degraded by proteasome.

In theory, this new mechanism can target all drug target proteins, especially those previously thought to be undruggable, thus expanding the field of drug research and promising prospects for new drugs R&D. PROTAC technology is novel and has many advantages compared with traditional micromolecule drugs, antibody drugs, RNAi.. It is considered one of the most popular new modalities in drug discovery and Medicilon is highly experienced in PROTAC development.

Learn more
Preparation of recombinant kinase
Our Biology Department has rich research experience in the preparation of recombinant kinases. We use various expression systems such as insect cell expression systems, HEK293 cell expression systems and E.coli expression systems. To support the selection, discovery and development of kinase targeting drugs, we provide a series of kinase research solutions ranging from detection method development, high-throughput selection to selective analysis. We actively communicate with our clients, understand their specific needs, and provide them with complete experimental technical solutions.
Learn more
In Vitro Evaluation of Antibodies

Monoclonal antibodies include an antigen-binding fragment (Fab) and a fragment crystallizable region (Fc). The Fab can bind to a tumor-associated antigen, while the Fc plays an important role in metabolic pathways, as well as in IgG-driven cellular functions.

The molecular sequence and subtype of antibodies will affect the effector functions. Such effector functions include the antibody dependent cellular cytotoxicity (ADCC) triggered by Fc binding to the FcγRIII receptor (CD16A) of NK. The Fc can also bind with serum complement molecules (C1q) to form a membrane attack complex (MAC) that triggers complement-dependent cytotoxicity (CDC). When Fc binds with macrophage receptors—namely FcγRIII (CD16A), FcγRII (CD32A) and FcγRI (CD64)—antibody-dependent cellular phagocytosis (ADCP) is triggered.

Learn more